Novel Combinatorial Strategy Using Thermal Inkjet Bioprinting, Chemotherapy, and Radiation on Human Breast Cancer...

Area of Science:

• Oncology
• Biotechnology
• Drug Development

Background:

• Breast cancer is a leading cause of mortality in women.
• Current in-vitro models for drug development have limitations.
• Novel bioprinting technology can improve in-vitro cancer modeling.

Purpose of the Study:

• To evaluate the sensitivity of breast cancer cells to palbociclib and letrozole using bioprinting.
• To determine if bioprinting can predict treatment outcomes more efficiently.
• To compare cell viability in bioprinted versus manually seeded cells.

Main Methods:

• Utilized breast cancer cell lines (MCF7, MDA-MB-231) and a normal cell line (MCF-10A).
• Treated cells with palbociclib (PD) and letrozole (Let), with and without radiotherapy (RT).
• Compared cell viability between thermally inkjet bioprinted (TIB) and manually seeded (MS) cells.

Main Results:

• TIB cells demonstrated higher viability than MS cells when treated with PD-Let, particularly in MCF7 cells.
• Bioprinted cells showed increased resistance to combination drug treatment compared to manually seeded cells.
• No significant difference in radiation resistance was observed between TIB and MS cells.

Conclusions:

• Thermally inkjet bioprinting (TIB) is a feasible strategy for in-vitro drug development.
• Bioprinting technology can enhance the prediction of anticancer drug efficacy.
• This approach may lead to more efficient testing of novel cancer therapeutics.